These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 31225773)

  • 1. Vortioxetine for Depression in Adults.
    Long JD
    Issues Ment Health Nurs; 2019 Sep; 40(9):819-820. PubMed ID: 31225773
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment effects on residual cognitive symptoms among partially or fully remitted patients with major depressive disorder: A randomized, double-blinded, exploratory study with vortioxetine.
    Nierenberg AA; Loft H; Olsen CK
    J Affect Disord; 2019 May; 250():35-42. PubMed ID: 30826492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-inflammatory treatment of depression: study protocol for a randomised controlled trial of vortioxetine augmented with celecoxib or placebo.
    Fourrier C; Sampson E; Mills NT; Baune BT
    Trials; 2018 Aug; 19(1):447. PubMed ID: 30126458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine.
    Montgomery SA; Nielsen RZ; Poulsen LH; Häggström L
    Hum Psychopharmacol; 2014 Sep; 29(5):470-82. PubMed ID: 25087600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relative short-term efficacy and acceptability of agomelatine versus vortioxetine in adult patients suffering from major depressive disorder.
    Kennedy SH; Grouin JM; Cadour S; Robert V; Picarel-Blanchot F
    Hum Psychopharmacol; 2018 Jan; 33(1):. PubMed ID: 29327372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Persisting decline in depression treatment after FDA warnings.
    Libby AM; Orton HD; Valuck RJ
    Arch Gen Psychiatry; 2009 Jun; 66(6):633-9. PubMed ID: 19487628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, double-blind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD.
    Mahableshwarkar AR; Jacobsen PL; Chen Y; Serenko M; Trivedi MH
    Psychopharmacology (Berl); 2015 Jun; 232(12):2061-70. PubMed ID: 25575488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suicidal ideation and behavior in adults with major depressive disorder treated with vortioxetine: post hoc pooled analyses of randomized, placebo-controlled, short-term and open-label, long-term extension trials.
    Mahableshwarkar AR; Affinito J; Reines EH; Xu J; Nomikos G; Jacobsen PL
    CNS Spectr; 2020 Jun; 25(3):352-362. PubMed ID: 31199210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Are selective serotonin reuptake inhibitors a risk factor for adolescent suicide?
    Healy D
    Can J Psychiatry; 2009 Feb; 54(2):69-71; discussion 76-7. PubMed ID: 19254434
    [No Abstract]   [Full Text] [Related]  

  • 10. Vortioxetine for the treatment of major depressive disorder.
    Tritschler L; Felice D; Colle R; Guilloux JP; Corruble E; Gardier AM; David DJ
    Expert Rev Clin Pharmacol; 2014 Nov; 7(6):731-45. PubMed ID: 25166025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Continuation treatment with antidepressants in child and adolescent major depression.
    Ryan ND
    Am J Psychiatry; 2008 Apr; 165(4):411-2. PubMed ID: 18381908
    [No Abstract]   [Full Text] [Related]  

  • 12. The treatment of SSRI-resistant depression in adolescents (TORDIA): in search of the best next step.
    Brent DA
    Depress Anxiety; 2009; 26(10):871-4. PubMed ID: 19798756
    [No Abstract]   [Full Text] [Related]  

  • 13. Vortioxetine: a New Treatment for Major Depressive Disorder.
    Connolly KR; Thase ME
    Expert Opin Pharmacother; 2016; 17(3):421-31. PubMed ID: 26679430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vortioxetine : a review of efficacy, safety and tolerability with a focus on cognitive symptoms in major depressive disorder.
    Al-Sukhni M; Maruschak NA; McIntyre RS
    Expert Opin Drug Saf; 2015 Aug; 14(8):1291-304. PubMed ID: 26022537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Digging for data on harms in duloxetine trials.
    Doshi P; Zito J; dosReis S
    BMJ; 2014 Jun; 348():g3578. PubMed ID: 24904123
    [No Abstract]   [Full Text] [Related]  

  • 16. [A new antidepressant: vortioxetine].
    Bazin C
    Soins Psychiatr; 2015; (296):8. PubMed ID: 25751904
    [No Abstract]   [Full Text] [Related]  

  • 17. Intravenous vortioxetine to accelerate onset of effect in major depressive disorder: a 2-week, randomized, double-blind, placebo-controlled study.
    Vieta E; Florea I; Schmidt SN; Areberg J; Ettrup A
    Int Clin Psychopharmacol; 2019 Jul; 34(4):153-160. PubMed ID: 31094901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A question of balance.
    Ramchandani P
    Nature; 2004 Jul; 430(6998):401-2. PubMed ID: 15269742
    [No Abstract]   [Full Text] [Related]  

  • 19. The use of antidepressants to treat depression in children and adolescents.
    Cheung AH; Emslie GJ; Mayes TL
    CMAJ; 2006 Jan; 174(2):193-200. PubMed ID: 16415467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective serotonin reuptake inhibitors in children and adolescents with major depression.
    Scahill L
    Braz J Psychiatry; 2005 Jun; 27(2):91-2. PubMed ID: 15962129
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.